Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This clinical trial is being done to determine if metformin, a drug which is normally used in
diabetes, can reduce atrial fibrillation in patients who are having an ablation for atrial
fibrillation (AF). Atrial fibrillation is an abnormal heart rhythm which research has shown
is related in part to obesity and diabetes.
It is anticipated that the participants treated in the metformin arm will have greater
freedom from recurrent atrial arrhythmias after ablation.
Eligible participants enrolled in the trial will be assigned to one of the treatment arms (no
treatment or metformin) and have follow-up visits up to approximately 1 year after the
ablation. Additionally, all patients will also receive education on lifestyle changes and
exercise which are standard of care.